Bia 3-202 (200 mg)    (DrugBank: BIA)

1 disease
IDDisease name (Link within this page)Number of trials
6Parkinson disease1

6. Parkinson disease    [ 2,123 clinical trials,   2,046 drugs,   (DrugBank: 324 drugs),   183 drug target genes,   198 drug target pathways]
Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 2,123 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02772614
(ClinicalTrials.gov)
January 200612/5/2016Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and MetabolitesAn Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and Metabolites Following a Single-dose Oral AdministrationParkinson's DiseaseDrug: BIA 3-202 (200 mg)Bial - Portela C S.A.NULLCompleted40 Years55 YearsMale4Phase 1Switzerland